Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial
PaperCitations, authors & open-access status
Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 621 citations, 2021 year and closed oa status.
621
Citations
2021
Year
closed
OA Status